PriceTargets.com logo

Repligen - RGEN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $196.70
  • Forecasted Upside: 17.18%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$167.86 As of 04/24/2024 01:00 AM ET
▼ -3.42 (-2.00%)

This chart shows the closing price for RGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Repligen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGEN

Analyst Price Target is $196.70
▲ +17.18% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is $196.70, with a high forecast of $220.00 and a low forecast of $165.00. The average price target represents a 17.18% upside from the last price of $167.86.

This chart shows the closing price for RGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 polled investment analysts is to moderate buy stock in Repligen. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2024Stifel NicolausBoost TargetBuy ➝ Buy$165.00 ➝ $207.00Low
2/15/2024KeyCorpBoost TargetOverweight ➝ Overweight$210.00 ➝ $220.00Low
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$170.00 ➝ $210.00Low
12/4/2023BenchmarkDowngradeBuy ➝ HoldLow
11/2/2023UBS GroupLower TargetBuy ➝ Buy$210.00 ➝ $170.00Low
11/1/2023Stifel NicolausLower TargetBuy ➝ Buy$200.00 ➝ $165.00Low
11/1/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$207.00 ➝ $200.00Low
11/1/2023KeyCorpLower TargetOverweight ➝ Overweight$240.00 ➝ $210.00Low
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$200.00 ➝ $180.00Low
9/6/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$191.00Low
8/3/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$157.00 ➝ $195.00Low
8/3/2023Craig HallumLower TargetBuy ➝ Buy$207.00 ➝ $200.00Low
8/3/2023StephensBoost TargetOverweight ➝ Overweight$180.00 ➝ $200.00Low
7/20/2023Wells Fargo & CompanyInitiated CoverageOverweight$185.00N/A
7/6/2023Royal Bank of CanadaUpgradeSector Perform ➝ OutperformLow
6/28/2023Stifel NicolausLower Target$210.00 ➝ $200.00Low
5/3/2023Deutsche Bank AktiengesellschaftLower Target$180.00 ➝ $165.00Low
5/3/2023Royal Bank of CanadaLower Target$170.00 ➝ $157.00Low
5/3/2023Craig HallumLower Target$220.00 ➝ $207.00Low
5/3/2023BenchmarkLower Target$230.00 ➝ $210.00Low
5/3/2023Stifel NicolausLower Target$225.00 ➝ $210.00Low
3/27/2023BenchmarkInitiated CoverageBuy$230.00Low
2/23/2023Craig HallumLower Target$251.00 ➝ $220.00Low
2/23/2023KeyCorpLower TargetOverweight$260.00 ➝ $240.00Low
1/6/2023SVB LeerinkLower TargetOutperform$230.00 ➝ $200.00Low
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold$180.00Low
12/6/2022Royal Bank of CanadaInitiated CoverageSector Perform$190.00Low
11/2/2022William BlairReiterated RatingOutperformLow
11/2/2022Craig HallumLower Target$274.00 ➝ $251.00Low
8/3/2022SVB LeerinkBoost TargetOutperform$220.00 ➝ $250.00Low
8/3/2022StephensBoost TargetOverweight$220.00 ➝ $275.00Low
8/3/2022KeyCorpBoost TargetOverweight$245.00 ➝ $260.00Low
7/20/2022UBS GroupInitiated CoverageBuy$213.00Low
4/28/2022Craig HallumLower Target$286.00 ➝ $274.00Medium
2/18/2022SVB LeerinkLower TargetOutperform$275.00 ➝ $250.00Low
12/20/2021SVB LeerinkReiterated RatingBuyHigh
10/29/2021SVB LeerinkBoost TargetOutperform$260.00 ➝ $325.00Low
10/14/2021Exane BNP ParibasInitiated CoverageOutperform$330.00High
10/14/2021BNP ParibasInitiated CoverageOutperform$330.00High
9/27/2021Craig HallumBoost TargetBuy$258.00 ➝ $368.00High
9/17/2021KeyCorpBoost TargetOverweight$255.00 ➝ $335.00High
8/20/2021StephensBoost TargetOverweight$255.00 ➝ $290.00Low
7/28/2021Craig HallumBoost TargetBuy$251.00 ➝ $258.00High
5/5/2021HC WainwrightBoost TargetBuy$225.00 ➝ $240.00Low
4/19/2021HC WainwrightReiterated RatingBuy$168.00 ➝ $225.00Medium
4/12/2021HC WainwrightBoost TargetBuy$168.00 ➝ $225.00Low
2/25/2021Craig HallumBoost TargetBuy$245.00 ➝ $251.00High
2/25/2021SVB LeerinkBoost TargetOutperform$220.00 ➝ $250.00High
1/20/2021Craig HallumBoost TargetBuy$229.00 ➝ $245.00High
11/9/2020KeyCorpInitiated CoverageOverweightHigh
8/24/2020HC WainwrightBoost TargetBuy$151.00 ➝ $168.00High
6/30/2020HC WainwrightReiterated RatingBuy$143.00 ➝ $151.00High
5/27/2020Stifel NicolausBoost TargetPositive ➝ Buy$135.00 ➝ $150.00High
5/7/2020Craig HallumBoost TargetBuy$120.00 ➝ $145.00Medium
5/7/2020SVB LeerinkBoost TargetOutperform$115.00 ➝ $150.00Medium
5/7/2020HC WainwrightBoost TargetBuy$100.00 ➝ $143.00Low
4/2/2020Stifel NicolausLower TargetBuy$116.00 ➝ $113.00Low
3/23/2020HC WainwrightLower TargetBuy$110.00 ➝ $100.00High
2/21/2020Stifel NicolausBoost TargetBuy$105.00 ➝ $116.00Medium
2/21/2020StephensBoost TargetOverweight$112.00 ➝ $114.00Medium
1/13/2020HC WainwrightReiterated RatingBuy$110.00High
11/14/2019Stifel NicolausInitiated CoverageBuy$105.00High
11/1/2019First AnalysisUpgradeOutperform ➝ Strong-Buy$107.00 ➝ $110.00High
10/15/2019SVB LeerinkReiterated RatingOutperform$100.00High
8/28/2019First AnalysisBoost TargetOutperform$95.00 ➝ $107.00Medium
8/22/2019StephensReiterated RatingOverweight$110.00Medium
8/12/2019HC WainwrightReiterated RatingBuy$110.00Low
8/5/2019Craig HallumBoost TargetBuy$80.00 ➝ $108.00High
7/22/2019HC WainwrightUpgradeNeutral ➝ Buy$110.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 8 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 11 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 11 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 18 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 23 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 13 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 13 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Repligen logo
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $167.86
Low: $165.91
High: $173.48

50 Day Range

MA: $186.62
Low: $157.06
High: $208.42

52 Week Range

Now: $167.86
Low: $110.45
High: $211.13

Volume

545,955 shs

Average Volume

538,751 shs

Market Capitalization

$9.37 billion

P/E Ratio

233.14

Dividend Yield

N/A

Beta

1.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Repligen?

The following Wall Street research analysts have issued stock ratings on Repligen in the last year: Benchmark Co., Craig Hallum, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., KeyCorp, Royal Bank of Canada, Stephens, Stifel Nicolaus, StockNews.com, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for RGEN.

What is the current price target for Repligen?

10 Wall Street analysts have set twelve-month price targets for Repligen in the last year. Their average twelve-month price target is $196.70, suggesting a possible upside of 17.2%. KeyCorp has the highest price target set, predicting RGEN will reach $220.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $165.00 for Repligen in the next year.
View the latest price targets for RGEN.

What is the current consensus analyst rating for Repligen?

Repligen currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RGEN.

What other companies compete with Repligen?

Other companies that are similar to Repligen include Acceleron Pharma, Exelixis, Neurocrine Biosciences, Halozyme Therapeutics and Denali Therapeutics. Learn More about companies similar to Repligen.

How do I contact Repligen's investor relations team?

Repligen's physical mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company's listed phone number is (781) 250-0111 and its investor relations email address is [email protected]. The official website for Repligen is www.repligen.com. Learn More about contacing Repligen investor relations.